Src activity has been identified as a mechanism of tumour resistance to oxaliplatin in metastatic CRC, suggesting that its pharmacological inhibition could enhance the efficacy of oxaliplatin-based chemotherapy in patients with CRC [55,139]. Here, SRC is linked to neoplasm.